HRP970326B1 - Process for preparing sildenafil - Google Patents

Process for preparing sildenafil

Info

Publication number
HRP970326B1
HRP970326B1 HR970326A HRP970326A HRP970326B1 HR P970326 B1 HRP970326 B1 HR P970326B1 HR 970326 A HR970326 A HR 970326A HR P970326 A HRP970326 A HR P970326A HR P970326 B1 HRP970326 B1 HR P970326B1
Authority
HR
Croatia
Prior art keywords
preparing sildenafil
sildenafil
preparing
Prior art date
Application number
HR970326A
Other languages
English (en)
Inventor
Peter James Dunn
Albert Shaw Wood
Original Assignee
Pfizer Res And Dev Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP970326(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Res And Dev Company filed Critical Pfizer Res And Dev Company
Publication of HRP970326A2 publication Critical patent/HRP970326A2/xx
Publication of HRP970326B1 publication Critical patent/HRP970326B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HR970326A 1996-06-14 1997-06-13 Process for preparing sildenafil HRP970326B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9612514.1A GB9612514D0 (en) 1996-06-14 1996-06-14 Novel process

Publications (2)

Publication Number Publication Date
HRP970326A2 HRP970326A2 (en) 1998-06-30
HRP970326B1 true HRP970326B1 (en) 2000-10-31

Family

ID=10795332

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970326A HRP970326B1 (en) 1996-06-14 1997-06-13 Process for preparing sildenafil

Country Status (48)

Country Link
US (2) US5955611A (ja)
EP (2) EP0916675B1 (ja)
JP (2) JP2866841B2 (ja)
KR (1) KR100207352B1 (ja)
CN (2) CN1106399C (ja)
AP (1) AP717A (ja)
AR (1) AR003401A1 (ja)
AT (2) ATE246194T1 (ja)
AU (1) AU697684B2 (ja)
BG (1) BG62554B1 (ja)
BR (1) BR9703580A (ja)
CA (1) CA2207694C (ja)
CO (1) CO4780028A1 (ja)
CZ (1) CZ290942B6 (ja)
DE (2) DE69723846T2 (ja)
DK (2) DK0812845T3 (ja)
DZ (1) DZ2247A1 (ja)
EA (1) EA000102B1 (ja)
EG (1) EG24123A (ja)
ES (2) ES2134051T3 (ja)
GB (1) GB9612514D0 (ja)
GR (1) GR3031087T3 (ja)
HK (1) HK1033459A1 (ja)
HN (1) HN1997000072A (ja)
HR (1) HRP970326B1 (ja)
HU (1) HU224497B1 (ja)
ID (1) ID18745A (ja)
IL (3) IL125411A (ja)
IN (5) IN187350B (ja)
IS (2) IS1922B (ja)
MA (1) MA24205A1 (ja)
MX (1) MX9704433A (ja)
NO (2) NO304551B1 (ja)
NZ (1) NZ328084A (ja)
OA (1) OA10426A (ja)
PE (2) PE20011303A1 (ja)
PL (1) PL189333B1 (ja)
PT (1) PT916675E (ja)
RS (2) RS49924B (ja)
SA (1) SA97180124B1 (ja)
SG (1) SG50024A1 (ja)
SI (2) SI0812845T1 (ja)
SK (5) SK283893B6 (ja)
TN (1) TNSN97102A1 (ja)
TR (1) TR199700470A2 (ja)
UA (1) UA27085C2 (ja)
UY (2) UY24585A1 (ja)
ZA (1) ZA975259B (ja)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
KR100390612B1 (ko) 1997-04-25 2003-07-07 화이자 인코포레이티드 타입 5 시클릭 구아노신 3',5'-모노포스페이트포스포디에스테라제를 억제하는 성기능 장애 치료용피라졸로피리미디논 제조용 중간체의 제조 방법
IL132993A0 (en) * 1997-05-29 2001-03-19 Mochida Pharm Co Ltd Therapeutic agent for erection failure
US6399618B1 (en) 1997-07-09 2002-06-04 Cardiome Pharma Corp Compositions and methods for modulating sexual activity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
ATE213246T1 (de) * 1997-11-12 2002-02-15 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
ATE247117T1 (de) * 1998-04-20 2003-08-15 Pfizer Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
CA2235642C (en) 1998-05-15 2007-11-13 Torcan Chemical Ltd. Processes for preparing sildenafil
ATE264861T1 (de) * 1998-09-04 2004-05-15 Ortho Mcneil Pharm Inc 5-heterozyklyl-pyrazolo(4,3-d)pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen
GB9822238D0 (en) * 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
CN1094492C (zh) * 1999-06-21 2002-11-20 杭州神鹰医药化工有限公司 西地那非的制备方法
WO2000078760A1 (fr) * 1999-06-21 2000-12-28 The Biochemical Pharmaceutical Factory Of Zhuhai Sez Procede de preparation de sildenafil, agent et procede d'obtention d'un comprime mixte a base de sildenafil et de chlorhydrate d'apomorphine
CN1077108C (zh) * 1999-07-13 2002-01-02 成都地奥制药集团有限公司 用于制备药物昔多芬的前体化合物
WO2001019827A1 (en) * 1999-09-13 2001-03-22 Cipla Ltd. A novel process for the synthesis of sildenafil citrate
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
BR0014695A (pt) 1999-10-11 2002-06-18 Pfizer 5-(2-substituìdo-5-heterociclilsulfonilpirid-3-il)-dihi dropirazolo[4,3-d]pirimidin-7-onas como inibidoras de fosfodiesterase
GB0015462D0 (en) * 2000-06-22 2000-08-16 Pfizer Ltd Novel process for the preparation of pyrazolopyrimidinones
US6730786B2 (en) * 2000-06-22 2004-05-04 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
US6667398B2 (en) 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
KR100525699B1 (ko) * 2000-06-22 2005-11-03 화이자 인코포레이티드 피라졸로피리미디논의 신규 제조 방법
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
EP1176147A1 (en) * 2000-07-28 2002-01-30 Pfizer Limited Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof
EP1176142A1 (en) * 2000-07-28 2002-01-30 Pfizer Inc. Process for the preparation of pyrazoles
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
ES2302835T3 (es) * 2001-08-28 2008-08-01 Schering Corporation Inhibidores de fosfodiesterasa v policiclicos de guanina.
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
CN100360531C (zh) * 2003-12-18 2008-01-09 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防或治疗阳萎和性冷淡的新吡唑并嘧啶类化合物
PL1633364T3 (pl) 2004-01-05 2008-07-31 Teva Pharma Sposób wytwarzania zasady sildenafilu i cytrynianu sildenafilu
EP1779852A3 (en) * 2004-01-05 2007-05-09 Teva Pharmaceutical Industries Ltd. Processes for the production of sildenafil base and citrate salt
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
US8071765B2 (en) * 2006-12-21 2011-12-06 Topharman Shanghai Co., Ltd. Process for the preparation of sildenafil and intermediates thereof
ES2310144B1 (es) 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
EP2374460A4 (en) 2008-12-12 2013-08-21 Rhein Siegfried Sa De Cv SILDENAFIL COMPOSITION WITH PULSED RELEASE AND METHOD FOR PRODUCING THIS COMPOSITION
MX2010006227A (es) 2010-06-07 2011-12-14 World Trade Imp Exp Wtie Ag Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
CN102993205B (zh) * 2012-12-27 2015-04-15 华润赛科药业有限责任公司 一种高收率制备高纯度西地那非游离碱的纯化方法
CN103044330B (zh) * 2013-01-14 2018-11-13 常州亚邦制药有限公司 西地那非中间体4-氨基-1-甲基-3-正丙基吡唑-5-甲酰胺的绿色合成新工艺
CN105085526B (zh) * 2014-05-15 2017-08-01 重庆圣华曦药业股份有限公司 一种改进的西地那非制备方法
CN105753870B (zh) * 2016-04-01 2018-05-22 重庆康刻尔制药有限公司 一种西地那非杂质f及其制备方法和应用
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN105837578A (zh) * 2016-04-05 2016-08-10 重庆康刻尔制药有限公司 一种西地那非杂质d的合成方法
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用
CN112961160A (zh) * 2021-03-05 2021-06-15 遂成药业股份有限公司 一种西地那非的改良合成工艺
CN113754612B (zh) * 2021-10-26 2023-09-26 山东安舜制药有限公司 一种西地那非中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871843A (en) * 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
KR100390612B1 (ko) * 1997-04-25 2003-07-07 화이자 인코포레이티드 타입 5 시클릭 구아노신 3',5'-모노포스페이트포스포디에스테라제를 억제하는 성기능 장애 치료용피라졸로피리미디논 제조용 중간체의 제조 방법
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
NO972481L (no) 1997-12-15
NO306115B1 (no) 1999-09-20
YU25497A (sh) 1998-12-23
IS6634A (is) 2002-11-25
SK283893B6 (sk) 2004-04-06
CA2207694A1 (en) 1997-12-14
BR9703580A (pt) 1998-11-10
HU9701048D0 (en) 1997-08-28
DZ2247A1 (fr) 2002-12-18
SK283894B6 (sk) 2004-04-06
UY24585A1 (es) 1997-12-02
GB9612514D0 (en) 1996-08-14
DK0916675T3 (da) 2003-10-27
SI0916675T1 (en) 2003-12-31
PL320555A1 (en) 1997-12-22
EP0916675A2 (en) 1999-05-19
EG24123A (en) 2008-07-06
AU697684B2 (en) 1998-10-15
EP0812845B1 (en) 1999-07-14
HUP9701048A3 (en) 2000-10-30
EP0916675A3 (en) 1999-07-14
TNSN97102A1 (fr) 2005-03-15
ID18745A (id) 1998-05-07
PT916675E (pt) 2003-11-28
RS49924B (sr) 2008-09-29
PE20011303A1 (es) 2001-12-25
DE69700321D1 (de) 1999-08-19
IN187319B (ja) 2002-03-23
JP3058863B2 (ja) 2000-07-04
IN187318B (ja) 2002-03-23
EA199700061A1 (ru) 1997-12-30
IS4503A (is) 1997-12-15
CN1149206C (zh) 2004-05-12
CZ290942B6 (cs) 2002-11-13
IL125411A0 (en) 1999-03-12
AR003401A1 (es) 1998-08-05
JPH11171879A (ja) 1999-06-29
DK0812845T3 (da) 1999-11-29
DE69723846D1 (de) 2003-09-04
CA2207694C (en) 1999-11-23
BG62554B1 (bg) 2000-02-29
CZ181197A3 (cs) 1998-03-18
KR100207352B1 (en) 1999-07-15
NO985064L (no) 1997-12-15
RS20060484A (en) 2007-04-10
MX9704433A (es) 1998-11-30
IS1922B (is) 2004-03-15
NZ328084A (en) 1998-08-26
PE1299A1 (es) 1999-01-13
IL125411A (en) 2000-02-29
SK283897B6 (sk) 2004-04-06
AP9701009A0 (en) 1997-07-31
IS1923B (is) 2004-03-15
IL121000A0 (en) 1997-11-20
GR3031087T3 (en) 1999-12-31
MA24205A1 (fr) 1997-12-31
IN187317B (ja) 2002-03-23
ES2201397T3 (es) 2004-03-16
NO304551B1 (no) 1999-01-11
ATE182150T1 (de) 1999-07-15
SA97180124A (ar) 2005-12-03
PL189333B1 (pl) 2005-07-29
AP717A (en) 1999-01-04
CO4780028A1 (es) 1999-05-26
RS49653B (sr) 2007-09-21
SI0812845T1 (en) 1999-12-31
AU2487897A (en) 1997-12-18
IL121000A (en) 2000-02-29
UA27085C2 (uk) 2000-02-28
CN1168376A (zh) 1997-12-24
HK1033459A1 (en) 2001-08-31
ATE246194T1 (de) 2003-08-15
DE69700321T2 (de) 1999-11-04
SK74397A3 (en) 1998-06-03
CN1282740A (zh) 2001-02-07
SK283896B6 (sk) 2004-04-06
EP0916675B1 (en) 2003-07-30
JPH1081688A (ja) 1998-03-31
CN1106399C (zh) 2003-04-23
SA97180124B1 (ar) 2006-02-08
HRP970326A2 (en) 1998-06-30
SG50024A1 (en) 1998-06-15
NO985064D0 (no) 1998-10-30
ZA975259B (en) 1997-12-15
HUP9701048A2 (hu) 1998-12-28
TR199700470A2 (xx) 1998-01-21
EP0812845A1 (en) 1997-12-17
JP2866841B2 (ja) 1999-03-08
IN187320B (ja) 2002-03-23
US6066735A (en) 2000-05-23
US5955611A (en) 1999-09-21
OA10426A (en) 2001-12-07
DE69723846T2 (de) 2004-03-04
ES2134051T3 (es) 1999-09-16
HU224497B1 (hu) 2005-10-28
BG101569A (en) 1998-01-30
EA000102B1 (ru) 1998-08-27
HN1997000072A (es) 1997-12-26
SK283895B6 (sk) 2004-04-06
UY24612A1 (es) 2000-09-29
KR980002051A (ko) 1998-03-30
NO972481D0 (no) 1997-05-30
IN187350B (ja) 2002-03-30

Similar Documents

Publication Publication Date Title
EG24123A (en) Process for preparing sildenafil
HUP9902419A3 (en) Process for preparing nitrobiphenylene
IL129761A0 (en) Method for preparing cyclopropylamines
IL134059A0 (en) Process for preparing aminoarylacetylenes
HUP9904325A3 (en) Process for johexol manufacture
EG23935A (en) Process for preparing eprosartin
IL122454A0 (en) Process for forming bubble-pack
EG22077A (en) Process for preparing 4-substituted-ih-indole-3 glyoxamides
IL126668A0 (en) Improved process for preparing ionones especially beta-ionones
GB2317178B (en) Process for preparing 1-chloromethylsilatrane
IL126184A (en) Process for preparing pentafluoropentanol
GB9626570D0 (en) Process for making benzisothiazolin-3-ones
HUP9904112A3 (en) Process for preparing amidines
IL133288A (en) Process for preparing 3-isochromanone
IL125646A (en) Process for preparing N-pyruvyl-L-proline
SI0888261T1 (en) Process for preparing nitrobiphenylene
GB9602856D0 (en) Process for preparing 4-tert-butyloxycarbonyl-(s) piperazine-2-tert-butylcarboxamide
FI102608B1 (fi) Menetelmä alkoholien valmistamiseksi
ZA987025B (en) Process for preparing 1-pyruvyl-L-proline
IL130950A (en) Process for preparing carboxamido-4-azasteroids
SG42360A1 (en) Process for the preparation of -caprolactam
IL129506A0 (en) Method for preparing trimethylbenzoquinone
HUP9903692A3 (en) Process for making dihydropyrimidinones
HUT71905A (en) Process for preparing 6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylate-3,4-boron-diacetates

Legal Events

Date Code Title Description
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
A1OB Publication of a patent application
B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: PFIZER OVERSEAS PHARMACEUTICALS, IE

PPPP Transfer of rights

Owner name: PFIZER IRELAND PHARMACEUTICALS, IE

Owner name: PFIZER FINANCE INTERNATIONAL LIMITED, IE

PNAN Change of the applicant name, address/residence

Owner name: PFIZER MANUFACTURING IRELAND, IE

PPPP Transfer of rights

Owner name: PFIZER IRELAND PHARMACEUTICALS (A PARTNERSHIP), IE

Owner name: PFIZER IRELAND PHARMACEUTICALS, IE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20120611

Year of fee payment: 16

PBON Lapse due to non-payment of renewal fee

Effective date: 20130614